Rongliflozin
A medication used for the treatment of type 2 diabetes
Rongliflozin is a pharmaceutical drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors), which work by preventing the reabsorption of glucose in the kidneys, thereby lowering blood sugar levels.
Mechanism of Action[edit | edit source]
Rongliflozin functions by inhibiting the SGLT2 protein in the proximal tubules of the kidney. This protein is responsible for the reabsorption of glucose from the urine back into the bloodstream. By blocking this protein, rongliflozin increases the excretion of glucose through the urine, which helps to lower blood glucose levels in patients with type 2 diabetes.
Pharmacokinetics[edit | edit source]
Rongliflozin is administered orally and is rapidly absorbed from the gastrointestinal tract. It has a bioavailability of approximately 60-70%. The drug is metabolized primarily in the liver and is excreted mainly through the urine. The half-life of rongliflozin is approximately 12 hours, allowing for once-daily dosing.
Clinical Use[edit | edit source]
Rongliflozin is indicated for the treatment of type 2 diabetes in adults. It is often used in combination with other antidiabetic medications such as metformin or insulin to achieve better glycemic control. The drug is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.
Side Effects[edit | edit source]
Common side effects of rongliflozin include urinary tract infections, increased urination, and hypoglycemia when used in combination with insulin or insulin secretagogues. Rare but serious side effects include ketoacidosis, acute kidney injury, and urosepsis.
Contraindications[edit | edit source]
Rongliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. It should also be used with caution in patients with a history of hypotension or electrolyte imbalances.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
